Lilly Antibody Combo Therapy Reduced Viral Levels in Study (1)

Eli Lilly and Co.’s combination antibody drug for Covid-19 reduced patients’ viral levels better than one of its components that’s already authorized for U.S. emergency use, a study found.

The component, called bamlanivimab, didn’t reduce viral load compared to placebo, according to a study published in the Journal of the American Medical Association. When combined with another antibody called etesevimab, though, there was a significant reduction compared with those who got a placebo.

The study found no difference between the monotherapy and combination in outcomes like hospitalization and deaths, a finding that should be more important to doctors than ...